TQT Analysis in Japanese and Caucasian Volunteers

Posted:
15
March 2011

As a feature of this year�s 84th annual meeting of the Japanese Pharmacological Society (JPS) taking place March 22nd to 24th in Yokohama Japan, the first ever formal Japanese Caucasian bridging TQT analysis is due to  be presented by Professor Sugiyama of Taiho University and Dr Jorg Taubel of Richmond Pharmacology Ltd.  The analysis was carried out jointly between the Department of Pharmacology of Toho University, the Cardiovascular Sciences Research Centre at St Georges University of London and Richmond Pharmacology Ltd.Japan and BeyondIn 2010, Japan adopted the ICH E14 guideline requiring the submission of TQT studies for new product license applications which may need to be done partly or fully in Japanese subjects.In 1998, the International Conference on Harmonisation (ICH)  Guideline on Ethnic Factors in the Acceptability of Foreign Clinical Data  (E5) was adopted.  This, coupled with the acceptance of the PDMA in 2007 of clinical data from non-Japanese patients, has helped to bring NCE s to the Japanese pharmaceutical market in both a cost and time efficient manner.Trust Well Invested (E5) was adopted.  This, coupled with the acceptance of the PDMA in 2007 of clinical data from non-Japanese patients, has helped to bring NCE

  • TQT Studies in Japanese and other ethnicities
  • First-in-Japanese
  • Ascending Single and Multiple  (SAD and MAD Studies)
  • Combined protocols such as bridging, SAD and MAD and food effect

Partnering with JapanIn order to facilitate the collaboration with Japanese sponsors, RICHMOND PHARMACOLOGY is also partnered with AcroNet, a Japan based full service clinical CRO.  Acronet provide a high quality, expert service and like Richmond Pharmacology, are dedicated to the development of the pharmaceutical and medical field and most importantly people's health.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more